Summary
Cancer Research UK (CRUK) is a research institution that offers clinical research services. The institute offers cancer research services for anal cancer, bile duct cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children's cancer, choriocarcinoma, chronic lymphocytic leukaemia, chronic myeloid leukaemia, colon cancer, colorectal cancer, endometrial cancer, eye cancer, gallbladder cancer and gastric cancer, among others. Its cancer treatment services comprise symptoms research, screening, tests, treatment and clinical trial services. The institute offers coping programs such as managing symptoms and side effects; counseling and talking; money and travel; death and dying and providing cancer-chat forums. CRUK is headquartered in London, the UK.
Cancer Research UK - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research UK, Medical Devices Deals, 2011 to YTD 2017 11
Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Cancer Research UK, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
GammaDelta Therapeutics Raises Funds through Seed Financing 17
ADC Therapeutics To Raise US$50 Million In Venture Financing 18
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 19
Partnerships 20
Cancer Research UK Enters into Agreement with Bicycle Therapeutics 20
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 21
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 22
Artios Pharma Research Agreement with Cancer Research Technology 23
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 23
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 24
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 25
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 26
Medivir Enters into Development Agreement with Cancer Research Technology 27
BioInvent and CRT Enter into Research Agreement with University of Southampton 27
Cancer Research UK Forms Joint Venture with MedImmune 28
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 29
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 30
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 31
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 32
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 33
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 34
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 35
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 36
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 42
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 43
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 44
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 46
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 47
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 49
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 50
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 51
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 52
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 53
Licensing Agreements 55
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 55
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 56
Cancer Research UK Enters into Licensing Agreement with Amgen 56
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 57
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 58
Merck Enters into Licensing Agreement with Cancer Research Technology 59
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 60
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 61
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 61
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 62
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 64
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 65
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 66
Affitech Enters Into Licensing Agreement With Cancer Research Technology 67
Cancer Research UK - Key Competitors 69
Key Employees 70
Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
List of Tables
Cancer Research UK, Pharmaceuticals & Healthcare, Key Facts 1
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research UK, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research UK, Medical Devices Deals, 2011 to YTD 2017 11
Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
GammaDelta Therapeutics Raises Funds through Seed Financing 17
ADC Therapeutics To Raise US$50 Million In Venture Financing 18
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 19
Cancer Research UK Enters into Agreement with Bicycle Therapeutics 20
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 21
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 22
Artios Pharma Research Agreement with Cancer Research Technology 23
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 23
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 24
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 25
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 26
Medivir Enters into Development Agreement with Cancer Research Technology 27
BioInvent and CRT Enter into Research Agreement with University of Southampton 27
Cancer Research UK Forms Joint Venture with MedImmune 28
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 29
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 30
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 31
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 32
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 33
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 34
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 35
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 36
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 38
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 39
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 40
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 41
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 42
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 43
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 44
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 46
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 47
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 49
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 50
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 51
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 52
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 53
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 55
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 56
Cancer Research UK Enters into Licensing Agreement with Amgen 56
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 57
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 58
Merck Enters into Licensing Agreement with Cancer Research Technology 59
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 60
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 61
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 61
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 62
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 64
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 65
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 66
Affitech Enters Into Licensing Agreement With Cancer Research Technology 67
Cancer Research UK, Key Competitors 69
Cancer Research UK, Key Employees 70
Cancer Research UK, Subsidiaries 71
List of Figures
Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Cancer Research UK, Medical Devices Deals, 2011 to YTD 2017 11
